Herantis Pharma Secures €8M Horizon 2025 Grant for Parkinson’s Drug Trial
Event summary
- Herantis Pharma secured a €8M grant from Horizon Europe 2025 for its Phase 2 trial of HER-096 in Parkinson’s disease.
- The funding supports a double-blind, placebo-controlled study set to begin after regulatory approvals and resource securing.
- HER-096 is a first-in-class small peptide designed to stop the progression of Parkinson’s disease.
- The grant is part of the Horizon Europe Health initiative aimed at accelerating biotech research into clinical development.
The big picture
Herantis Pharma’s €8M grant underscores the growing emphasis on translating biotech research into clinical therapies, particularly for neurodegenerative diseases. The funding aligns with broader EU initiatives to bolster SME competitiveness in health biotech and accelerate access to innovative treatments. This strategic validation could enhance Herantis’ ability to attract additional investment and partnerships as it progresses HER-096 through clinical development.
What we're watching
- Trial Execution
- The pace at which Herantis can initiate the Phase 2 trial following regulatory approvals and securing additional resources.
- Funding Strategy
- Whether Herantis can leverage this non-dilutive funding to attract further investment or strategic partnerships.
- Competitive Positioning
- How the validation from Horizon Europe impacts Herantis’ standing in the competitive landscape of Parkinson’s disease therapies.
Related topics